EICHOR
● Completed
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Condition: Locally Advanced or Metastatic Unresectable Urothelial Cancer · Sponsor: Gilead Sciences
About this study
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (234)
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | — |
| UCLA Hematology/ Oncology | Los Angeles, California, United States | — |
| University of California Irvine (UCIMC) | Orange, California, United States | — |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| Baptist MD Anderson Cancer Center | Jacksonville, Florida, United States | — |
| Boca Raton Clinical Research Global USA - Plantation | Plantation, Florida, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | — |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | — |
| Roswell Park Cancer Institute | Buffalo, New York, United States | — |
| Weill Cornell Medical College | New York, New York, United States | — |
| Montefiore Medical Center | The Bronx, New York, United States | — |
+ 222 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04527991